cbdMD Completes Self-Affirmed GRAS Determination for CBD Safety
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 20 hours ago
0mins
Source: Newsfilter
- Safety Research Milestone: cbdMD announced the completion of its self-affirmed GRAS determination, supporting a daily intake of up to 200 mg of CBD for healthy adults, which enhances consumer and healthcare professional confidence due to years of scientific investment in safety evidence.
- Data Accumulation: The company has developed a substantial body of safety data through studies in rodents, healthy human volunteers, and canines, covering toxicology, genotoxicity, and human tolerability, further solidifying its market position in the hemp-derived CBD sector.
- Policy Opportunity: In 2026, the CMS launched a first-of-its-kind patient access incentive for non-intoxicating CBD, and cbdMD's safety research provides policymakers with scientific backing to integrate CBD products into mainstream healthcare, advancing industry standardization.
- Market Positioning Advantage: This safety affirmation gives cbdMD a clear daily intake reference point, supporting the development of products across various formats and use occasions, thereby enhancing the company's competitive edge in both direct-to-consumer and healthcare-oriented channels.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy YCBD?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on YCBD
Wall Street analysts forecast YCBD stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.712
Low
2.00
Averages
2.00
High
2.00
Current: 0.712
Low
2.00
Averages
2.00
High
2.00
About YCBD
cbdMD, Inc. is a consumer wellness company focused on the development, manufacturing, marketing, and sale of supplement brands powered by natural compounds. Its hemp-derived cannabinoids, include full-spectrum cannabidiol (CBD) formulations, hemp-derived Delta-9 THC products and a range of functional products designed to address key wellness needs, such as sleep, recovery, mood, discomfort, mobility, cognitive function, and stress management. It operates a multi-brand portfolio anchored by its flagship cbdMD line, which offers oils, gummies, capsules, soft-gels, topicals, functional formulations, and hemp-derived compliant Delta-9 THC products. Its Paw CBD pet-wellness brand provides tinctures, chews, and topicals for dogs and cats. Its ATRX platform offers non-cannabinoid functional ingredients such as functional mushrooms. Its Herbal Oasis (Oasis) brand is a premium hemp-derived THC-infused social seltzer that blends cannabinoids and nootropic mushrooms.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
cbdMD Completes Self-Affirmed GRAS Determination for CBD Safety
- Safety Research Milestone: cbdMD announced the completion of its self-affirmed GRAS determination, supporting a daily intake of up to 200 mg of CBD for healthy adults, which enhances consumer and healthcare professional confidence due to years of scientific investment in safety evidence.
- Data Accumulation: The company has developed a substantial body of safety data through studies in rodents, healthy human volunteers, and canines, covering toxicology, genotoxicity, and human tolerability, further solidifying its market position in the hemp-derived CBD sector.
- Policy Opportunity: In 2026, the CMS launched a first-of-its-kind patient access incentive for non-intoxicating CBD, and cbdMD's safety research provides policymakers with scientific backing to integrate CBD products into mainstream healthcare, advancing industry standardization.
- Market Positioning Advantage: This safety affirmation gives cbdMD a clear daily intake reference point, supporting the development of products across various formats and use occasions, thereby enhancing the company's competitive edge in both direct-to-consumer and healthcare-oriented channels.
See More
cbdMD Welcomes Federal Hemp Regulation Reform
- Call for Regulatory Reform: cbdMD welcomes the Administration's push for Congress to ensure fair treatment of hemp-derived products, emphasizing the importance of this reform for industry transparency and compliance, which could enhance the company's competitiveness in a maturing market.
- Market Legitimacy Progress: With major U.S. exchanges beginning to allow compliant operators to list, cbdMD, as a publicly listed company, is well-positioned in the industry's move towards greater legitimacy and transparency, likely attracting more investment and attention.
- CEO Emphasizes Responsible Regulation: cbdMD's CEO Ronan Kennedy states that the future success of the market relies on quality, transparency, and clear rules, which will help distinguish responsible operators from bad actors, thereby enhancing consumer trust.
- Long-Term Value Commitment: cbdMD plans to focus on providing effective products and supporting responsible regulation in the evolving market environment, reflecting the company's proactive stance towards long-term value creation for shareholders and potential growth opportunities.
See More
cbdMD Appoints New CMO to Drive Brand Expansion
- Leadership Appointment: cbdMD has appointed Wade Brown as Chief Marketing Officer, who has been pivotal since joining in March 2025 in stabilizing the brand portfolio and supporting the acquisition of Bluebird Botanicals, which is expected to further drive growth in the health and wellness sector.
- Revenue Growth: cbdMD recently reported a 19% year-over-year and 12% sequential revenue growth, attributed to continued momentum in its core brands and the integration of Bluebird, demonstrating the company's ability to maintain strong performance in a competitive market.
- Multi-Brand Strategy: Brown will oversee marketing and commercial growth across brands like cbdMD, Paw CBD, Oasis, and Bluebird Botanicals, aiming to evolve the company into a broader multi-brand wellness platform encompassing CBD, pet, botanical, and functional health categories.
- Market Execution Capability: Brown emphasized the importance of modern growth systems across DTC, Amazon, and retail channels, indicating his focus on building an operating system that creates lasting value for customers and shareholders, further solidifying cbdMD's leadership in the consumer health space.
See More
cbdMD to Announce Q1 Earnings on May 14
- Earnings Announcement Schedule: cbdMD (YCBD) is set to release its Q1 2026 earnings report on May 14 after market close, with investors keen to assess the company's financial performance for future growth potential.
- EPS Expectations: Analysts forecast a consensus EPS of -$0.05, reflecting a significant year-over-year improvement of 77.3%, indicating a potential rebound in the company's profitability.
- Revenue Projections: The revenue estimate stands at $5.29 million, representing a 3.5% year-over-year increase, suggesting a positive sales growth trend for cbdMD, despite ongoing profitability challenges.
- Market Reaction Anticipation: Investors will closely monitor the upcoming earnings report to evaluate cbdMD's financial health and future growth strategies, which could significantly impact its stock price movements.
See More
cbdMD to Host Conference Call for Q2 Financial Results
- Conference Call Details: cbdMD will host a conference call on May 14, 2026, at 4:20 p.m. Eastern Time to discuss its Q2 financial results as of March 31, 2026, which is expected to draw investor interest.
- Participation Information: Investors can join the call by dialing 888-880-3330, and a webcast replay link will be available until May 14, 2027, allowing those unable to attend live to catch up on the discussion.
- Company Overview: cbdMD is one of the leading CBD companies in the U.S., offering a comprehensive range of THC-free CBD products and Farm Act compliant Delta 9 products, showcasing its strong market position in the industry.
- Brand Diversity: cbdMD's Paw CBD and ATRx brands provide veterinarian-formulated pet products and functional mushroom products, respectively, while also launching Herbal Oasis, highlighting its innovative capabilities in the health beverage market.
See More
cbdMD Launches Clinical Channel to Support Cannabinoid Products
- Clinical Channel Launch: cbdMD announced the launch of its clinical healthcare channel on April 1, 2026, aimed at supporting physicians and health systems by leveraging federal policy to establish structured pathways for cannabinoid products, thereby enhancing the company's competitive position in the healthcare market.
- CMS Policy Activation: The Centers for Medicare & Medicaid Services (CMS) published guidance on March 20, 2026, allowing eligible hemp-derived products to be used in Medicare programs for the first time, which is expected to benefit thousands of physicians and millions of Medicare beneficiaries.
- Safety Data Advantage: cbdMD possesses a unique clinical and toxicological safety dataset, including OECD-standard preclinical toxicology studies and human randomized controlled trial data, ensuring the safety and efficacy of its products in clinical settings, thus increasing trust among physicians and healthcare systems.
- Market Integration Potential: cbdMD is actively engaging in research partnerships with healthcare organizations and academic institutions to generate real-world outcomes data, promoting the clinical integration of hemp CBD products in Medicare settings and further expanding its market share.
See More
cbdMD Completes Self-Affirmed GRAS Determination for CBD Safety
- Safety Research Milestone: cbdMD announced the completion of its self-affirmed GRAS determination, supporting a daily intake of up to 200 mg of CBD for healthy adults, which enhances consumer and healthcare professional confidence due to years of scientific investment in safety evidence.
- Data Accumulation: The company has developed a substantial body of safety data through studies in rodents, healthy human volunteers, and canines, covering toxicology, genotoxicity, and human tolerability, further solidifying its market position in the hemp-derived CBD sector.
- Policy Opportunity: In 2026, the CMS launched a first-of-its-kind patient access incentive for non-intoxicating CBD, and cbdMD's safety research provides policymakers with scientific backing to integrate CBD products into mainstream healthcare, advancing industry standardization.
- Market Positioning Advantage: This safety affirmation gives cbdMD a clear daily intake reference point, supporting the development of products across various formats and use occasions, thereby enhancing the company's competitive edge in both direct-to-consumer and healthcare-oriented channels.
See More
cbdMD Welcomes Federal Hemp Regulation Reform
- Call for Regulatory Reform: cbdMD welcomes the Administration's push for Congress to ensure fair treatment of hemp-derived products, emphasizing the importance of this reform for industry transparency and compliance, which could enhance the company's competitiveness in a maturing market.
- Market Legitimacy Progress: With major U.S. exchanges beginning to allow compliant operators to list, cbdMD, as a publicly listed company, is well-positioned in the industry's move towards greater legitimacy and transparency, likely attracting more investment and attention.
- CEO Emphasizes Responsible Regulation: cbdMD's CEO Ronan Kennedy states that the future success of the market relies on quality, transparency, and clear rules, which will help distinguish responsible operators from bad actors, thereby enhancing consumer trust.
- Long-Term Value Commitment: cbdMD plans to focus on providing effective products and supporting responsible regulation in the evolving market environment, reflecting the company's proactive stance towards long-term value creation for shareholders and potential growth opportunities.
See More
cbdMD Appoints New CMO to Drive Brand Expansion
- Leadership Appointment: cbdMD has appointed Wade Brown as Chief Marketing Officer, who has been pivotal since joining in March 2025 in stabilizing the brand portfolio and supporting the acquisition of Bluebird Botanicals, which is expected to further drive growth in the health and wellness sector.
- Revenue Growth: cbdMD recently reported a 19% year-over-year and 12% sequential revenue growth, attributed to continued momentum in its core brands and the integration of Bluebird, demonstrating the company's ability to maintain strong performance in a competitive market.
- Multi-Brand Strategy: Brown will oversee marketing and commercial growth across brands like cbdMD, Paw CBD, Oasis, and Bluebird Botanicals, aiming to evolve the company into a broader multi-brand wellness platform encompassing CBD, pet, botanical, and functional health categories.
- Market Execution Capability: Brown emphasized the importance of modern growth systems across DTC, Amazon, and retail channels, indicating his focus on building an operating system that creates lasting value for customers and shareholders, further solidifying cbdMD's leadership in the consumer health space.
See More
cbdMD to Announce Q1 Earnings on May 14
- Earnings Announcement Schedule: cbdMD (YCBD) is set to release its Q1 2026 earnings report on May 14 after market close, with investors keen to assess the company's financial performance for future growth potential.
- EPS Expectations: Analysts forecast a consensus EPS of -$0.05, reflecting a significant year-over-year improvement of 77.3%, indicating a potential rebound in the company's profitability.
- Revenue Projections: The revenue estimate stands at $5.29 million, representing a 3.5% year-over-year increase, suggesting a positive sales growth trend for cbdMD, despite ongoing profitability challenges.
- Market Reaction Anticipation: Investors will closely monitor the upcoming earnings report to evaluate cbdMD's financial health and future growth strategies, which could significantly impact its stock price movements.
See More
cbdMD to Host Conference Call for Q2 Financial Results
- Conference Call Details: cbdMD will host a conference call on May 14, 2026, at 4:20 p.m. Eastern Time to discuss its Q2 financial results as of March 31, 2026, which is expected to draw investor interest.
- Participation Information: Investors can join the call by dialing 888-880-3330, and a webcast replay link will be available until May 14, 2027, allowing those unable to attend live to catch up on the discussion.
- Company Overview: cbdMD is one of the leading CBD companies in the U.S., offering a comprehensive range of THC-free CBD products and Farm Act compliant Delta 9 products, showcasing its strong market position in the industry.
- Brand Diversity: cbdMD's Paw CBD and ATRx brands provide veterinarian-formulated pet products and functional mushroom products, respectively, while also launching Herbal Oasis, highlighting its innovative capabilities in the health beverage market.
See More
cbdMD Launches Clinical Channel to Support Cannabinoid Products
- Clinical Channel Launch: cbdMD announced the launch of its clinical healthcare channel on April 1, 2026, aimed at supporting physicians and health systems by leveraging federal policy to establish structured pathways for cannabinoid products, thereby enhancing the company's competitive position in the healthcare market.
- CMS Policy Activation: The Centers for Medicare & Medicaid Services (CMS) published guidance on March 20, 2026, allowing eligible hemp-derived products to be used in Medicare programs for the first time, which is expected to benefit thousands of physicians and millions of Medicare beneficiaries.
- Safety Data Advantage: cbdMD possesses a unique clinical and toxicological safety dataset, including OECD-standard preclinical toxicology studies and human randomized controlled trial data, ensuring the safety and efficacy of its products in clinical settings, thus increasing trust among physicians and healthcare systems.
- Market Integration Potential: cbdMD is actively engaging in research partnerships with healthcare organizations and academic institutions to generate real-world outcomes data, promoting the clinical integration of hemp CBD products in Medicare settings and further expanding its market share.
See More
